Company news
Cellbxhealth Plc (LSE:CLBX) news
Every Cellbxhealth Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Parsortix CTCs used for Brain Cancer detection
August 11, 2026
Parsortix CTCs used for ADC target assessment
August 3, 2026
Q2 and First Half Year Results ended 30 June 2026
July 15, 2026
Directorate change
July 6, 2026
MSA with Global Pharmaceutical Company
May 29, 2026
Collaboration with AdventHealth for two studies
May 18, 2026
Q1 trading update and outlook for 2026
May 11, 2026
Confirmation of Q1 trading update
April 30, 2026
Research Collaboration with The Royal Marsden
April 20, 2026
Board changes - Replacement
April 16, 2026
Aligning Regulatory Approach with Commercial Needs
February 13, 2026
CelLBxHealth PLC Announces Preliminary Fourth Quarter 2025 Financial Results
January 16, 2026
CelLBxHealth PLC Announces Board Changes
January 12, 2026
Cellbxhealth PLC Announces Holding(s) in Company
December 23, 2025
PDMR Dealing and ESOT Share Purchase
December 19, 2025
Results of General Meeting and Board Changes
December 15, 2025
Additional Subscription
December 2, 2025
Result of Retail Offer
December 1, 2025
Update to Admission of Fundraising Shares
November 25, 2025
Proposed Placing and Subscription
November 24, 2025
QIAGEN Collaboration and Co-Marketing Agreement
November 18, 2025
CelLBxHealth PLC Presents Proof-of-Concept Study
November 5, 2025
Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding
November 4, 2025
CHANGE OF NAME
October 29, 2025
Appointments: Interim CEO and senior board advisor
October 16, 2025
Strategy Update
October 8, 2025
Presentation of Data on Glioblastoma
September 29, 2025
Board Changes
September 12, 2025
Interim Results
September 9, 2025
Notice of Results
September 5, 2025
ANGLE announces collaboration with Myriad Genetics
August 20, 2025
PARSORTIX ENABLES STUDY OF CANCER PROGRESSION
July 8, 2025
Result of 2025 Annual General Meeting
June 30, 2025
EACR 2025: Innovation in AR expression profiling
June 17, 2025
Novel discoveries into the biology of cancer
June 10, 2025
POSTING OF ANNUAL REPORT AND NOTICE OF AGM
June 9, 2025
Preliminary Results
May 28, 2025
RESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
April 28, 2025
Issue of LTIP Options and Share Options
March 21, 2025
Novel findings using Parsortix
February 6, 2025
Analysis of CTC-DNA and ctDNA using Illumina assay
January 29, 2025
Parsortix used in research paper from ETH Zurich
January 24, 2025
Trading Update
January 23, 2025
HER2 presentation at SABCS
December 13, 2024
Research on HER2 assay kit showcased at AACR
November 15, 2024
ANGLE presents two posters at EACR
November 13, 2024
Parsortix enriched CTC & ctDNA in NSCLC patients
November 11, 2024
Publication demonstrates CTC profiling potential
October 17, 2024
100th publication supporting Parsortix system use
September 26, 2024
Exclusive agreement for DNA NGS panel
September 23, 2024